Community Member
a year agoI finished 6 rounds of Chemotherapy including Ketruda for triple negative. The Ketruda has caused a nasty body rash on the last 3 infusions. I am to have surgery and then 9 more rounds of Ketruda. My oncologist is recommending Dupixent for the rash. It is expensive and not sure it will work. Is Ketruda the only immunotherapy drug that will work? Isn't there an alternative?
Accepted Answer
This sounds like a really challenging situation with the rash making your treatment more difficult. While Ketruda is commonly used for triple negative breast cancer, there are other immunotherapy options that oncologists sometimes consider, though the best choice depends on many individual factors that only your medical team can fully evaluate. It might be worth having a detailed conversation with your oncologist about all available alternatives and whether switching medications could be appropriate for your specific case, especially since you're experiencing such uncomfortable side effects.
3+ patients found this helpful
Community Member
6 months agoIm on keytruda immunotherapy and carboplatin and paxtaxol cocktail . Had my breast removed while pregnant in october 2024 and just finished 27 days of radiation in December2024. I haven’t had a rash but eye twitches and stomach cramping.
Community Member
2 months agoThis sounds like a really challenging situation with the rash making your treatment more difficult. While Ketruda is commonly used for triple negative breast cancer, there are other immunotherapy options that oncologists sometimes consider, though the best choice depends on many individual factors that only your medical team can fully evaluate. It might be worth having a detailed conversation with your oncologist about all available alternatives and whether switching medications could be appropriate for your specific case, especially since you're experiencing such uncomfortable side effects.
New to the community?
Create an account to connect with others navigating cancer.
© 2025 Outcomes4Me Inc. All rights reserved.